Get the latest Science News and Discoveries

Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers - EurekAlert


Researchers from Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, have discovered a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, the Company’s proprietary generative AI platform.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of deficient cancers

deficient cancers

Photo of EurekAlert

EurekAlert

Photo of Generative AI

Generative AI

Related news:

News photo

Computer scientist William Wang receives prestigious early career technical achievement award - EurekAlert

News photo

Common HIV treatments may aid Alzheimer’s dis - EurekAlert

News photo

Oregon State researchers advance pigment chemistry with moon-inspired reddish magentas - EurekAlert